Skip to main content
. Author manuscript; available in PMC: 2010 Nov 23.
Published in final edited form as: Vaccine. 2009 Sep 26;27(50):7087–7095. doi: 10.1016/j.vaccine.2009.09.059

Figure 3. SDS-PAGE and Western Blot analysis of EP-1043 recombinant protein.

Figure 3

EP-1043 drug substance (0.75 μg) was separated by SDS-PAGE on a 12% gel (panel A, lane 2) and stained with Coomassie Blue; molecular weight standards are shown in panel A, lane 1. The protein bands were quantitated using scanning densitometry and the major band represents >85% of the total detected protein; product release specification was 80%. An equivalent sample was analyzed by Western Blot using rabbit antisera specific for the synthetic peptide derived from the EP-1043 protein to demonstrate the identity of the major band to EP-1043 protein (panel A, lane 3). EP-1043 drug product was analyzed using SDS-PAGE and Coomassie Blue staining following storage at 2–8° C for up to 2 years to demonstrate stability (panel B).